-
Eli Lilly and Company et al v. Teva Parenteral Medicines Inc., et al DC CAFC
- 1:08-cv-00335
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 06/05/2008
- Closed: 08/16/2011
- Latest Docket Entry: 09/30/2013
- PACER
- Docket updated daily
2
Plaintiffs
3
Defendants
1
Accused
Product
1
Patent-in-Suit
1,168
Days in
Litigation
-
Eli Lilly and Company et al v. Teva Parenteral Medicines Inc., et al DC CAFC
- 1:08-cv-00335
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 06/05/2008
- Closed: 08/16/2011
- Latest Docket Entry: 09/30/2013
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A compound of the formula: ##STR14## in which: R.sup.1 is --OH or --NH.sub.2 ; R.sup.2 is hydrogen or a pharmaceutically acceptable cation: R.sup.3 is 1,4-phenylene unsubstituted or substituted with chloro, fluoro, methyl, methoxy, or
view more
|
Valid
Entry 115 |
| 2 |
A compound according to claim 1 wherein R.sup.1 is --OH; R.sup.3 is 1,4-phenylene, and R.sup.4 is hydrogen.
|
Valid
Entry 115 |
| 3 |
The compound according to claim 1 which is N-{4-[2-(4-hydroxy-6-aminopyrrolo[2,3-d]pyrimidin-3-yl)ethyl]benzoyl}-L-gl utamic acid.
|
Valid
Entry 115 |
| 7 |
A compound of the formula: ##STR15## in which: R.sup.1 is --OH or --NH.sub.2 ; R.sup.2' is hydrogen, a pharmaceutically acceptable cation, or a carboxy protecting group: R.sup.3 is 1,4-phenylene unsubstituted or substituted with chloro, fluoro,
view more
|
Valid
Entry 115 |
-
Infringement
APP Pharmaceuticals LLC
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Pemetrexed Disodium for Injection, Eq. 500 mg Base/Vial | US 5,344,932 A |
1, 2, 3, 7
|
Infringement
Entry 115
|
Teva Parenteral Medicines
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Pemetrexed Disodium for Injection, Eq. 500 mg Base/Vial | US 5,344,932 A |
1, 2, 3, 7
|
Infringement
Entry 115
|
